FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A

The US Food and Drug Administration approved Fayuvi (rebisufligene etisparvovec-hopf), establishing the first direct therapeutic intervention for children with mucopolysaccharidosis type IIIA (MPS IIIA). The condition, caused by mutations in the SGSH gene, leads to severe central nervous system degeneration and childhood mortality through the toxic accumulation of heparan sulfate. The approved protocol uses an adeno-associated virus vector to deliver a functional copy of human SGSH directly into brain tissue via a one-time surgical administration.

Clinical endpoints in the trial data submitted to the FDA tracked reductions of heparan sulfate in cerebrospinal fluid by more than 70 percent, accompanied by sustained stabilization in cognitive developmental scores compared to historical controls. Until this decision, pediatric palliative pathways managed symptoms without addressing metabolic arrest. The availability of a restorative biological mechanism shifts genetic screening from passive risk documentation into time-critical intervention.

For parents managing undiagnosed developmental plateaus, early whole-genome sequencing combined with validated algorithmic interpretation offers practical utility. You can request raw variant data files from diagnostic panels and verify whether secondary findings include rare lysosomal storage markers, securing clinical guidance before symptom onset limits intervention windows.